Information updates


13 July 2020

Further to updates made in early 2020, the ASCIA Hereditary Angioedema (HAE) Position Paper has recently been updated in response to the New Zealand Minister of Health’s recent consent to the distribution of lanadelumab (published in the New Zealand Gazette on Tuesday 23 June 2020). 

The following statement has been included on page 12:

Lanadelumab is registered for prophylaxis of HAE attacks in New Zealand but is not yet funded. For those patients where it may be appropriate a NPPA application could be made to Pharmac. The recommended dose is 300mg SC every two weeks.

The updated ASCIA HAE Position Paper is available on the ASCIA website


Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.